HonorStocks Biotech Gold Oil Mining China Asian MENU
Biotech Gold Oil Mining China Asian
Find Tomorrow's Winners Today

Stock technical analysis
Rating Flag Rating Flag Rating Flag Rating Flag Rating Flag
sell neutral buy
Intercept Pharmaceuticals, Inc. (ICPT)
47.09  0.57  (1.23%) 07-03 16:29
Open: 47.21 High: 47.23
Pre.close: 46.52 Low: 45.0762
Volume: 1,118,744 Ave vol: 894,733
52w High: 125 52w Low: 44.5
MA(50): 75.62 MA(200): 86.009
EPS: -10.737 P/E Ratio: 0
Company profile
Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.interceptpharma.com
Market Cap (M): 1,551
Shares Out (M): 33
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. Its lead products candidate is the Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults. The company is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis (NASH); and several other product candidates in various stages of clinical and preclinical development. It has a license agreement with Sumitomo Dainippon Pharma Co. Ltd. for the research, development, and commercialization of OCA as a therapeutic for the treatment of PBC and NASH in Japan and China; and Aralez Pharmaceuticals Canada Inc to develop and commercialize bezafibrate in the United States.
Technical analysis
Overall: Neutral
MA: Bearish MACD: Bearish
KDJ: Bullish RSI: Bullish
Target 1: 80.18 Target 2: 97.61
Resist 1: 68.65 Resist 2: 83.57
Support 1: 44.50 Support 2: 37.02
Company key metrics
Revenue per Share: 7.9611
Net Income per Share: -10.889
Cash per Share: 2.2131
Book Value per Share: 1.6287
Price to Sales: 11.5913
Price to Book Value: 56.6574
Earnings Yield: -0.118
Dividend Yield: 0
Debt to Equity: 13.6421
Debt to Assets: 0.9317
Financial analysis
Price to Book Value: Underperform
Return on Assets: Underperform
Return on Equity: Outperform
Discounted cash flow: Outperform
Price to Earnings: Underperform
Debt to Equity: Underperform
Stock Charts
Headline news
Tue, 23 Jun 2020
Is Intercept Pharmaceuticals Inc (ICPT) Going to Burn These Hedge Funds? - Yahoo Finance

Tue, 30 Jun 2020
Analysts Are Downgrading Intercept Pharmaceuticals. Here’s Why. - Barron's

Mon, 29 Jun 2020
Why Intercept Pharmaceuticals Stock Is Crashing Today - Motley Fool

Wed, 01 Jul 2020
Should You Throw in the Towel on Intercept Pharmaceuticals After Its Big Setback? - Motley Fool

Sun, 28 Jun 2020
Intercept Pharmaceuticals, Inc. (ICPT) Seems To Be Turning Some Investors Off - Invest Million

Thu, 02 Jul 2020
Where Does Wall Street Think Intercept Pharmaceuticals Inc (ICPT) Stock Will Go? - InvestorsObserver

HonorStocks, Find Tomorrow's Winners Today

©HonorStocks.com | U.S. stock markets, stock quotes and stock analysis. Data and information is provided for informational purposes only, is not intended for trading purposes and is not investment advice. Neither HonorStocks.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Market data provided by: IEX and Financial Modeling Prep

Privacy Policy: Third parties, including Google, may be placing and reading cookies on your browsers, or other methods to collect information as a result of ad serving on this website. Google's use of advertising cookies enables it and its partners to serve ads to you based on your visit to this site and/or other sites on the Internet. You may opt out of personalized advertising by visiting Ads Settings. If you choose to use this website, you agree to the collection and use of information in relation to this policy. The information collected is used for providing and improving the ads Service. We will not use or share information with anyone, and we do not store any data from users.